Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Dr. Leighl's Highlights in Lung Cancer, 2012: ALK- and ROS1-positive NSCLC
Author
Howard (Jack) West, MD

ALK positiveDr. Leighl, lung cancer expert from Princess Margaret Hospital in Toronto, continued her summary of the leading highlights in lung cancer from 2012 with coverage of new information on XALKORI for patients with either an ALK rearrangement or the newly identified ROS-1 rearrangement.  

The video and audio versions of the podcast on this part of her program are below, along with the figures:

[powerpress]

Dr. Leighl Highlights in LC 2012 Pt 2 ALK and ROS Rearr NSCLC Audio Podcast

Dr. Leighl Highlights in LC 2012 Pt 2 ALK and ROS Rearr NSCLC Figs

More of her presentation coming very soon!

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora